Related Experiment Video
Updated: Apr 7, 2026
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Five-year inhaled, systemic, and total corticosteroid exposure reduction during anti‒interleukin-5 receptor alpha
Kjell Erik Julius Håkansson1, Susanne Hansen1, Marianne Baastrup Soendergaard1
1Department of Respiratory Medicine and Infectious Diseases‒Bispebjerg, Copenhagen University Hospital, Copenhagen, Denmark.
Background:
Anti-interleukin-5 receptor alpha (IL-5Rα) therapy for severe asthma has indicated marked reductions in systemic corticosteroid use. However, little is known about the long-term total (inhaled and systemic) corticosteroid exposure.
Objective:
To estimate total corticosteroid exposure reduction and prevalence of corticosteroid remission over 5 years of anti-IL-5Rα therapy for severe asthma.
Methods:
All Danish adults in whom anti-IL-5Rα for severe asthma was initiated during 2016 to 2019 were observed for 5 years. Corticosteroid exposure was assessed annually using national registries, and changes were estimated using mixed models. Corticosteroid remission was defined as no systemic corticosteroid exposure and low-to-moderate daily inhaled corticosteroid doses.
Results:
In total, 253 patients were included (median age 57 years, 51% female). At baseline, 33% were using daily maintenance oral corticosteroids. The year before biologic therapy, median total corticosteroid exposure was 3604 mg (3404, 3803) prednisolone equivalents. In year 1, total corticosteroid exposure was reduced by 25.2% (13.4, 36.9), increasing to a reduction of approximately 45% in years 3 through 5. Systemic corticosteroids accounted for most reductions, with decreases of 32.8% (21.1, 44.6) during the first year and approximately 60% during later years. For inhaled corticosteroids, statistically significant reductions were observed during year 4 at -149.7 µg budesonide equivalents (-13.7, -285.7) and -189.1 µg (-23.2, -355.1) during year 5. During later treatment years, inhaled corticosteroids represented the primary source of corticosteroid exposure. Corticosteroid remission was achieved in an annual average of 23% whereas 5-year sustained corticosteroid remission was achieved in only 2.4%.
Conclusion:
Over 5 years, anti-IL-5Rα treatment significantly reduced total corticosteroid exposure. Reductions were driven by marked reductions in systemic corticosteroid exposure, whereas modest reductions in inhaled corticosteroid exposure were observed.
Related Concept Videos
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...